Bristol Myers Squibb drug Augtyro now has a tumor-agnostic approval permitting the drug to be used to treat all solid tumors positive for NTRK gene fusions. Augtyro came from BMS’s $4.1 billion acquisition of Turning Point Therapeutics.
The post New FDA Nod Brings Bristol Myers Squibb Cancer Drug to a Wider Range of Solid Tumors appeared first on MedCity News.
Related Articles
Red Alert about Red Buttons
By KIM BELLARD In a week where, say, the iconic brand Tupperware...
Weight Loss Surgery Outshines GLP-1 Drugs in Preserving Kidney Health
Bariatric surgery may protect kidney function better than GLP-1 drugs in people...
How Health Systems Can Bridge Gaps in Health Equity
To effectively address health disparities, organizations must implement health equity strategies that...
Leave a comment